The gap in fatigue research – and what we’re doing about it, 31 July 2023, The Kennedy Trust & Arthritis UK

InitialConditions said:
What comprises 'the blurb' here? And what's wrong with it?
Click to expand...

The article is the blurb. I don't see any insight into biological processes. It just seems to be an exercise in putting ducks in a row without knowing what you are going to do with them when they are in a row.

I find it hard to see the point of studying fatigue in condition slike rheumatoid because if you treat the disease effectively with something like a TNF inhibitor or rituximab the fatigue vanishes. It might be interesting to dissect out various signal pathways to fatigue but I don't see much evidence of that being addressed here.
 
From the article

How can we tackle fatigue?
To address these problems, Arthritis UK (then Versus Arthritis) and The Kennedy Trust held a workshop in 2020 to identify priorities for future research into fatigue.

The workshop brought together a range of healthcare professionals and researchers from diverse backgrounds, alongside people with lived experience. They identified areas of research where Arthritis UK (then Versus Arthritis) and The Kennedy Trust could work together to make an impact on the lives of people living with musculoskeletal fatigue.

“For many, fatigue is overlooked, under-prioritised, and not understood. Together we will address this most significant of unmet healthcare needs for people living with musculoskeletal, and other long-term, conditions.
Arthritis UK and The Kennedy Trust fatigue steering group

As a result of the workshop, we decided we wanted to better understand existing evidence and inform future research.

Together, we decided the first step would be to fund a piece of work to look closely at current fatigue research.

This project will explore what is already known on the ways of measuring, assessing and treating severe fatigue associated with rheumatic and related musculoskeletal conditions. The project will take a life course approach and consider fatigue in children, young people and adults.

Now, we’re excited to announce that Professor Emma Dures has been awarded funding to carry out this important review with her team at the University of the West of England (UWE) starting August 2023. The UWE team will work with collaborators at University College London (UCL) and the University of Aberdeen.
Click to expand...

This seems to be that review,
Andy

Thread 'Instruments for measuring fatigue in people with rheumatic and musculoskeletal diseases: a systematic review of measurement properties 2025 Machado+'

Authors: Eduardo José Ferreira Santos, Bayram Farisogullari, Katie Fishpool, George Young, Coziana Ciurtin, Fiona Cramp, Emmanuel Oghenetejiri Erhieyovwe, Gary J Macfarlane, Jen Pearson, Emma Dures, Pedro M Machado

Abstract​

Objective To summarise the measurement properties of instruments used to assess fatigue in people with rheumatic and musculoskeletal diseases (RMDs).

Methods A systematic review (SR) of measurement properties was conducted in children, adolescents/young adults and adults with RMDs, following Joanna Briggs Institute and COSMIN (COnsensus-based...
  • Like

Dures is also an author on these studies
Dolphin

Trial Report Thread 'Exploring the content validity of the Chalder Fatigue Scale using cognitive interviewing in an ME/CFS population, 2024, Gladwell'

Free full text:
https://www.tandfonline.com/doi/full/10.1080/21641846.2024.2335861

Research Article
Exploring the content validity of the Chalder Fatigue Scale using cognitive interviewing in an ME/CFS population
Peter Gladwell
Matthew Harland
Aysha Adrissi
Saskia Kershaw
&
Emma Dures
Received 11 Dec 2023, Accepted 25 Mar 2024, Published online: 06 Apr 2024

ABSTRACT
Background
The Chalder Fatigue Scale, also known as the Chalder Fatigue Questionnaire...
  • Like

Andy

Thread 'cognitive behavioural and personalised exercise interventions for fatigue in inflammatory rheumatic diseases (LIFT), 2022, Bachmair et al'

Merged
Abstract here


Brief Summary:
Fatigue is common and disabling for most patients with inflammatory rheumatic disease. Therapies designed to improve physical activity and 'talking' treatments, which positively help patients change the way they think and behave, are both helpful in reducing the burden of the fatigue. However, few patients have access to these treatments in most health services. This situation results from the absence of standardised programmes and limited availability of relevant therapists.

The investigators aim to enhance access to fatigue...
Click to expand...
  • Like
 
The Kennedy Trust funded this study
Andy

Thread 'Long-COVID fatigue is not predicted by pre-pandemic plasma IL-6 levels in mild COVID-19 2023 Freidin, Pariante, Williams et al'

Abstract

Objective and design: Fatigue is a prominent symptom in the general population and may follow viral infection, including SARS-CoV2 infection which causes COVID-19. Chronic fatigue lasting more than three months is the major symptom of the post-COVID syndrome (known colloquially as long-COVID). The mechanisms underlying long-COVID fatigue are unknown. We hypothesized that the development of long-COVID chronic fatigue is driven by the pro-inflammatory immune status of an individual prior to COVID-19.

Subjects and methods: We analyzed pre-pandemic...
  • Like
 
From this work, they aim to:
  • recommend ways of measuring fatigue for healthcare professionals and researchers.
Click to expand...
Oh joy, more PROMS!
  • understand the current evidence behind existing treatments and what is needed for them to be delivered effectively.
Click to expand...
There are none, except for the ones that treat the root cause: the disease.
  • define fatigue from the perspective of people living with musculoskeletal fatigue.
Click to expand...
Even more PROMS and psychosocial babble.
  • identify gaps in the support available for fatigue along with the groups of people whose healthcare needs are currently not being met.
Click to expand...
Are they aiming to create some kind of support for anyone with untreated fatigue, as if it’s all the same?
 
Jonathan Edwards said:
I find it hard to see the point of studying fatigue in condition slike rheumatoid because if you treat the disease effectively with something like a TNF inhibitor or rituximab the fatigue vanishes. It might be interesting to dissect out various signal pathways to fatigue but I don't see much evidence of that being addressed here.
Click to expand...
That's an odd perspective. It seems to be common in medicine, and explains so much, especially the lack of incremental progress. In most engineering fields, this is the stuff that drives us. We want to figure things out, especially odd puzzles like this. Sometimes just knowing, seeing where it takes us, drives everything we do, and damn is it massively successful.

Turning medicine into an information engineering problem will absolutely change everything, and it's not just something nice, but an existential need. Everything is so slow in there.
 
You must log in or register to reply here.
Back
Top Bottom